NUVB:NYSENuvation Bio Inc. Analysis
Data as of 2026-04-21 - not real-time
$5.15
Latest Price
8/10Risk
Risk Level: High
Executive Summary
NUVB is trading near the upper end of its recent range with technical signals turning bullish – the MACD line sits above its signal line and the histogram is positive, while the RSI is approaching overbought levels. Volume has been slipping, suggesting a potential slowdown in buying pressure, yet the price remains comfortably above the identified support zone and below the nearest resistance.
Recent regulatory milestones, including the validation of the marketing authorisation application for taletrectinib in Europe, have added a catalyst to the narrative, aligning with a strong analyst consensus of a buy recommendation. However, the company’s fundamentals show negative earnings, substantial cash burn and a high price‑to‑book multiple, indicating that the market is pricing in significant growth expectations that are not yet reflected in cash flow.
Recent regulatory milestones, including the validation of the marketing authorisation application for taletrectinib in Europe, have added a catalyst to the narrative, aligning with a strong analyst consensus of a buy recommendation. However, the company’s fundamentals show negative earnings, substantial cash burn and a high price‑to‑book multiple, indicating that the market is pricing in significant growth expectations that are not yet reflected in cash flow.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- bullish MACD crossover
- RSI nearing overbought but still supportive
- recent positive regulatory validation
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- pipeline advancement for taletrectinib and safusidenib
- analyst consensus of strong buy
- potential upside relative to current price
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- high cash burn and negative cash flow
- elevated volatility and beta
- long‑term market opportunity in ROS1‑positive cancers
Key Metrics & Analysis
Financial Health
Revenue Growth633.10%
P/E Ratio-35.5
ROE-53.18%
ROA-23.46%
Debt/Equity21.90
P/B Ratio5.8
Op. Cash Flow$-173427008
Free Cash Flow$-115776248
Industry P/E26.0
Technical Analysis
TrendNeutral
RSI64.0
Support$4.05
Resistance$5.23
MA 20$4.59
MA 50$4.89
MA 200$4.85
MACDBullish
VolumeDecreasing
Fear & Greed Index87.59
Valuation
Target Price$12.33
Upside/Downside139.71%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.00
Volatility43.59%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.